

Freedom of Information Request

Ref: 20-351

17 December 2020

By Email

Dear Sir/Madam

Thank you for your request for information under the Freedom of Information Act 2000. The Trust's response is as follows:

- We can confirm that we do hold the information you are requesting

1. How many patients were treated within your Trust with the following drugs within the specified time periods?

Drug Number of patients treated between 01 February 2017 and 31 July 2018 Number of patients treated between 01 August 2018 and 31 January 2020

01 February 2017 and 31 July 2018

Apremilast	26
Adalimumab	741
Dupilumab	18
Etanercept	272
Infliximab	300
Secukinumab	45
Ustekinumab	137

01 August 2018 and 31 January 2020

Apremilast	48
Adalimumab	994
Dupilumab	72
Etanercept	236
Infliximab	305
Secukinumab	72
Ustekinumab	152

2. How many patients were treated within your Trust for atopic dermatitis within the specified time periods?

Number of patients treated for atopic dermatitis between 01 February 2017 and 31 July 2018 Number of patients treated for atopic dermatitis between 01 August 2018 and 31 January 2020

01 February 2017 and 31 July 2018 41

01 August 2018 and 31 January 2020 89

3. How many patients were treated within your Trust with the following drugs for atopic dermatitis within the specified time periods?

Drug Number of patients treated for atopic dermatitis between 01 February 2017 and 31 July 2018 Number of patients treated for atopic dermatitis between 01 August 2018 and 31 January 2020

01 February 2017 and 31 July 2018

Apremilast	0
Adalimumab	0
Dupilumab	0
Etanercept	0
Infliximab	1
Secukinumab	0
Ustekinumab	0

01 August 2018 and 31 January 2020

Apremilast	0
Adalimumab	0
Dupilumab	0
Etanercept	0
Infliximab	1
Secukinumab	0
Ustekinumab	0

4. Please specify how patients treated with the following drugs are coded (OPCS code) within your trust:

Drug OPCS code (e.g. X385 subcutaneous immunotherapy)

Apremilast Due to the nature of the data we use from Pharmacy, we unable to provide OPCS codes for this drug listed as we don't collect these now

Adalimumab X921

Dupilumab Due to the nature of the data we use from Pharmacy, we unable to provide OPCS codes for this drug listed as we don't collect these now

Etanercept X921

Infliximab X921
Secukinumab Unknown
Ustekinumab X891

5. Please provide the number of patients treated in the homecare setting for atopic dermatitis within the specified time periods:

01 February 2017 and 31 July 2018 1

01 August 2018 and 31 January 2020 5

6. How many of your Trust's homecare patients were treated with the following drugs for atopic dermatitis within the specified time periods?

Drug Number of patients treated for atopic dermatitis between 01 February 2017 and 31 July 2018 Number of patients treated for atopic dermatitis between 01 August 2018 and 31 January 2020

01 February 2017 and 31 July 2018

Apremilast	0
Adalimumab	0
Dupilumab	0
Etanercept	0
Infliximab	0
Secukinumab	0
Ustekinumab	0

01 August 2018 and 31 January 2020

Apremilast	1
Adalimumab	1
Dupilumab	0
Etanercept	0
Infliximab	0
Secukinumab	0
Ustekinumab	0

This concludes our response. We trust that you find this helpful, but please do not hesitate to contact us directly if we can be of any further assistance.

If, after that, you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to:

Director of Corporate Governance
University Hospitals Bristol and Weston NHS Foundation Trust

Trust Headquarters
Marlborough Street
Bristol
BS1 3NU

Please remember to quote the reference number above in any future communications.

If you are not content with the outcome of the internal review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF

Publication

Please note that this letter and the information included/attached will be published on our website as part of the Trust's Freedom of Information Publication Log. This is because information disclosed in accordance with the Freedom of Information Act is disclosed to the public, not just to the individual making the request. We will remove any personal information (such as your name, email and so on) from any information we make public to protect your personal information.

To view the Freedom of Information Act in full please click [here](#).

Yours sincerely

Freedom of Information Team
University Hospitals Bristol and Weston NHS Foundation Trust